G. R. Hudes

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

Bruce J. Roth, Robert Dreicer, Lawrence H. Einhorn et al. · Journal of Clinical Oncology · 1994 · 325 citations

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

G. R. Hudes, Faith E. Nathan, Carine Khater et al. · Journal of Clinical Oncology · 1997 · 273 citations

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

G. R. Hudes, Richard E. Greenberg, Robert L. Krigel et al. · Journal of Clinical Oncology · 1992 · 256 citations

Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

Sulabha Ranganathan, C A Benetatos, PJ Colarusso et al. · British Journal of Cancer · 1998 · 214 citations · Full text

Urology, Genitourinary Cancer, Medicine +5

A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)

G. R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · Journal of Clinical Oncology · 2006 · 210 citations

Immunology, Pharmacotherapy, Thrombosis +20